Group 1: Mergers and Acquisitions - Haili Biological's subsidiary, Ruisheng Biological, plans to invest 61.2 million yuan to acquire 51% equity in seven dental chain companies located in Yangzhou and Changzhou, which is expected to increase the company's revenue by approximately 100 million yuan and net profit by over 7 million yuan [1] - Yanggu Huatai has decided to terminate the issuance of shares and cash payment to acquire 99.64% equity in Bomi Technology, opting to negotiate for partial equity acquisition in cash instead [2] - Yachuang Electronics intends to issue shares and pay cash totaling 317 million yuan to purchase 40% equity in Shenzhen Ouchuang Semiconductor and 45% equity in Shenzhen Yihai Nengda, constituting a major asset restructuring [3] Group 2: Earnings Forecasts - Guangku Technology anticipates a net profit attributable to shareholders of 169 million to 182 million yuan for 2025, representing a year-on-year growth of 152% to 172% [4] Group 3: Shareholding Changes - Jianzhijia's actual controller, Yunnan Xiangqun, plans to increase its stake in the company by up to 2% through a concentrated bidding process, with an investment amount of 50 million yuan sourced from its own funds and a loan of up to 45 million yuan from CITIC Bank [5] - Zhenzhong Investment, a significant shareholder of Lvdiaofeng, plans to reduce its stake by no more than 1% through a concentrated bidding process, equating to a maximum of 680,000 shares [6] - Two shareholders of Lingzhi Software plan to reduce their holdings by a combined total of up to 1.43%, with one shareholder reducing by up to 3.281 million shares (0.82% of total shares) and the other by up to 2.4492 million shares (0.61% of total shares) [7] Group 4: Tax Issues - Tianyue Advanced announced that it needs to pay a total of 82.9728 million yuan in corporate income tax and late fees, which will be recorded in the 2025 financial results, expected to reduce the company's net profit for that year [8] - China Pharmaceutical's wholly-owned subsidiary, Hainan Tongyong Sanyang Pharmaceutical and Hainan Kangli Pharmaceutical, received tax notices requiring a total payment of approximately 65.2178 million yuan in taxes and late fees, which will also impact the company's net profit for 2025 [9][10] Group 5: Regulatory Issues - Platelite has received a notice from the China Securities Regulatory Commission regarding a case of suspected illegal information disclosure, leading to an official investigation [11] Group 6: Legal Matters - Baotailong announced that its subsidiary, Shuangyashan Longmei Tiantai Coal Chemical Co., is involved in a significant lawsuit that has entered the second instance, with a ruling requiring it to pay 316 million yuan in contract price and interest, while also receiving compensation and a return of a quality guarantee deposit [12]

Group 1 - The actual controller's concerted action partner, Yunnan Xiangqun, plans to increase its stake in Jianzhijia by 50 million yuan [1] - Shareholder Wu Aijun of ST Lutong intends to reduce his holdings by no more than 3% of the company's shares [1] - Shareholders Zhou Ying and Liang Qihua of Lingzhi Software plan to collectively reduce their holdings by no more than 1.43% of the company's shares [1] Group 2 - Shareholder Zhenzhong Investment of Green Island Wind intends to reduce its holdings by no more than 1% of the company's shares [1] - Director Chen Youfu of Shuanglin Co., Ltd. plans to reduce his holdings by no more than 0.02% of the company's shares [1]

证券代码：605266 证券简称：健之佳 公告编号：2026-001 健之佳医药连锁集团股份有限公司 关于实际控制人的一致行动人以自有资金及专项贷款增持公司股份 计划的公告 重要内容提示： 增持主体的基本情况：健之佳医药连锁集团股份有限公司（以下简称"公 司"）实际控制人之一蓝波 100%控股的云南祥群投资有限公司（以下简称"云南 祥群"）持有公司 13,818,299 股股份，占公司总股本的 8.9414%。含云南祥群在 内，公司实际控制人蓝波、舒畅夫妇及其一致行动人合计持有公司 63,007,569 股股份，占公司总股本的 40.7703%。 增持计划的主要内容：近日，公司收到云南祥群的《关于增持公司股份 的告知函》，云南祥群拟自本公告披露日起 6 个月内通过上海证券交易所交易系 统以集中竞价交易方式增持公司 A 股股份，增持总金额 5,000 万元，资金来源为 自有资金及股票增持专项贷款。 本次增持计划不触及要约收购，不会导致公司控股股东及实际控制人发生变 化。 增持计划无法实施风险：可能存在因资本市场变化等目前尚无法预判的 因素，导致本次增持计划无法按期完成的风险，敬请广大投资者注意投资风险。 | 增 ...

Group 1 - The company Jianzhijia (605266.SH) announced that it received a notice from Yunnan Xiangqun regarding their plan to increase shareholding in the company [1] - Yunnan Xiangqun intends to increase its stake in Jianzhijia through centralized bidding on the Shanghai Stock Exchange within six months from the announcement date [1] - The total amount for the share purchase is set at 50 million yuan, funded by self-owned capital and a special loan for stock acquisition [1]

（文章来源：第一财经） 健之佳公告，公司近日收到实际控制人的一致行动人云南祥群的《关于增持公司股份的告知函》，云南 祥群拟自本公告披露日起6个月内通过上海证券交易所交易系统以集中竞价交易方式增持公司A股股 份，增持总金额5000万元，拟增持股份比例不超过总股本的2%，资金来源为自有资金及股票增持专项 贷款。 ...

人民财讯12月31日电，健之佳（605266）12月31日公告，公司实际控制人的一致行动人云南祥群投资有 限公司(简称"云南祥群")拟自本公告披露日起6个月内通过上交所交易系统以集中竞价交易方式增持公 司A股股份，增持总金额5000万元，资金来源为自有资金及股票增持专项贷款。 ...

Core Viewpoint - The company announced that its actual controller, Lan Bo, through Yunnan Xiangqun, holds 13.8183 million shares, accounting for 8.9414% of the total shares, and together with concerted actors, holds a total of 63.0076 million shares, representing 40.7703% of the total shares [1] Summary by Relevant Sections - **Shareholding Structure** - Lan Bo, the actual controller, holds 13.8183 million shares, which is 8.9414% of the total shares [1] - Together with concerted actions, the total shareholding amounts to 63.0076 million shares, or 40.7703% of the total shares [1] - **Planned Share Buyback** - Yunnan Xiangqun plans to increase its stake in the company through a centralized bidding process on the Shanghai Stock Exchange from January 1, 2026, to June 30, 2026 [1] - The total amount for the buyback is set at 50 million yuan, funded by self-owned funds and a special loan from CITIC Bank not exceeding 45 million yuan, with a term of three years [1] - The buyback will not exceed 2% of the total share capital and will not trigger a mandatory tender offer [1]

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.0% on December 30, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3965.12, also down by 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Yingte Group (000411) with a closing price of 13.23, up by 9.98% and a trading volume of 419,800 shares [1] - Yao Yigou (300937) at 35.65, up by 7.64% with 125,700 shares traded [1] - HeFu China (603122) at 26.00, up by 6.17% with a trading volume of 985,200 shares [1] - Conversely, Saily Medical (603716) saw a decline of 3.19% to a closing price of 20.95, with a trading volume of 123,200 shares [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 258 million yuan from institutional investors, while retail investors contributed a net inflow of 54.61 million yuan [2] - Notable capital flows included: - HeFu China (603122) with a net inflow of 286 million yuan from institutional investors [3] - Yingte Group (000411) with a net inflow of 134 million yuan from institutional investors [3] - Yao Yigou (300937) with a net inflow of 16.36 million yuan from institutional investors [3]

Group 1 - The pharmacy sector experienced a short-term decline, with stocks such as Shuyupingmin falling over 6% [1] - Other companies in the sector, including First Pharmaceutical, Dazhenglin, Yixintang, and Jianzhijia, also saw a drop in their stock prices [1]

Group 1 - The pharmacy sector has experienced a short-term decline, with major companies such as Xu Yu Ping Min falling over 6% [1] - Other companies in the sector, including First Pharmaceutical, Dazhenglin, Yixintang, and Jianzhijia, have also seen declines in their stock prices [1]